Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sales of Ethical Drugs Down 0.3% in July: Crecon Report
September 20, 2010
- Anti-Flu Virus Agent Inavir Approved: Daiichi Sankyo
September 20, 2010
- MSD Aims at Entering Top 3 in Japan within 5 Years: Mr Alvarez
September 20, 2010
- TM Marketing to Be Renamed Anterio
September 20, 2010
- Abbott Applies for Norvir's Tablet Formulation
September 20, 2010
- Zeria to Acquire Biofac of Denmark
September 20, 2010
- Application Filed for Once-Monthly Tablets of Recalbon/Bonoteo
September 20, 2010
- Ono Licenses 2 Proteasome Inhibitors from Onyx
September 20, 2010
- Chugai to Apply for Xeloda Based on Data from Public Domain
September 20, 2010
- Shionogi Licenses 2 SLIT Tablets from Stallergenes
September 20, 2010
- Ancaron Approved for Additional Indication Based on Data from Public Domain
September 20, 2010
- ViiV to Continue Its Commitment to HIV Area: President Iriyama
September 20, 2010
- Multaq Recommended as First-Line Option for AF in ESC GL
September 20, 2010
- Bayer to Embark on Esthetic Dermatology Business
September 20, 2010
- Earlier Access to Unapproved Drugs Proposed at Chuikyo
September 20, 2010
- Overall Price Settlement Rate at 28.1% as of the End of June
September 20, 2010
- Pfizer to Undertake Development of Injectable Metronidazole
September 20, 2010
- Evidence on Diovan Accumulated in Japanese Patients
September 13, 2010
- Daiichi Sankyo Revises 1st Half FY2010 Business Forecasts Upward
September 13, 2010
- ACOS Focuses on Therapeutic Cancer Vaccines
September 13, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…